Epilepsy Franchise

Drug-resistant epilepsy is characterized by the persistence of seizures despite the use of at least two appropriate antiseizure medications at effective doses.

Despite the availability of over 20 ASMs, achieving seizure control in DRE patients remains difficult.

Leading experts in Epilepsy

Joseph Sullivan, MD

Pediatric neurologist, director of the UCSF Pediatric Epilepsy Center. One of the key leaders in Dravet Syndrome research

Dennis Dlugos, MD

Professor of neurology and pediatrics at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania School of Medicine.

Jackie French, MD

Professor of Neurology in the Comprehensive Epilepsy Center at NYU Langone School of Medicine and Founder/Director of the Epilepsy Study Consortium

Roger J. Porter, MD

Adjunct Professor of Neurology at the Univ. of Pennsylvania and Adjunct Professor of Pharmacology at USUHS; he has served as Chief Scientific Officer of the Epilepsy Foundation

Terrence O’Brien, MD

Chair of Medicine, Monash University, and Deputy Director of Research, Alfred Health. Chair of The Australian Epilepsy Clinical Trial Network

Jo Sourbron, MD, PhD

Medical doctor at UZ Ghent. Research focus on novel serotonergic compounds for drug-resistant epilepsies

Transforming Epilepsy Treatment

Pioneering Solutions for Drug-Resistant Epilepsy

Epilepsy affects over 70 million people worldwide, and approximately one-third of these individuals suffer from drug-resistant epilepsy (DRE), where seizures persist despite treatment with multiple antiseizure drugs. Our mission is to address this significant unmet need by developing innovative therapies that target the root causes of epilepsy.

 

Our Breakthrough Approach

Harnessing the Power of 5-HT2C Agonists

Our lead candidate BMB-101,a novel 5-HT2C agonist, represents a new frontier in epilepsy treatment. By targeting specific serotonin receptors, we aim to reduce seizure frequency and improve the quality of life for patients with drug-resistant epilepsy.

 

Why It Matters

Addressing the Urgent Need for Effective Therapies

Drug-resistant epilepsy not only increases the risk of premature death and injuries but also significantly impacts the psychosocial well-being and quality of life of those affected. Our research is dedicated to overcoming these challenges and providing hope to patients and their families.

 

 Join Us on Our Journey

Innovating for a Seizure-Free Future

We are committed to transforming the landscape of epilepsy treatment through rigorous research and development. Our team is driven by the potential to make a meaningful difference in the lives of those living with epilepsy.